0000950123-11-051597.txt : 20110518 0000950123-11-051597.hdr.sgml : 20110518 20110518143926 ACCESSION NUMBER: 0000950123-11-051597 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20110517 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20110518 DATE AS OF CHANGE: 20110518 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SAFEGUARD SCIENTIFICS INC CENTRAL INDEX KEY: 0000086115 STANDARD INDUSTRIAL CLASSIFICATION: INVESTORS, NEC [6799] IRS NUMBER: 231609753 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-05620 FILM NUMBER: 11854590 BUSINESS ADDRESS: STREET 1: 435 DEVON PARK DR STREET 2: BLDG 800 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 6102930600 MAIL ADDRESS: STREET 1: 435 DEVON PARK DR STREET 2: BLDG 800 CITY: WAYNE STATE: PA ZIP: 19087 FORMER COMPANY: FORMER CONFORMED NAME: SAFEGUARD INDUSTRIES INC DATE OF NAME CHANGE: 19810525 FORMER COMPANY: FORMER CONFORMED NAME: SAFEGUARD CORP DATE OF NAME CHANGE: 19690521 8-K 1 c17563e8vk.htm FORM 8-K Form 8-K
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 17, 2011
Safeguard Scientifics, Inc.
(Exact name of registrant as specified in its charter)
         
Pennsylvania   1-5620   23-1609753
         
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer Identification No.)
     
435 Devon Park Drive,
Building 800, Wayne, PA
   
19087
     
(Address of principal executive offices)   (Zip Code)
Registrant’s telephone number, including area code: 610-293-0600
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 


 

ITEM 1.01. Entry into a Material Definitive Agreement.
On May 17, 2011, Safeguard Scientifics, Inc. (“Safeguard”) partner company, Advanced BioHealing, Inc., and certain related parties (“ABH”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Shire Pharmaceuticals, Inc. and certain related parties (“Shire”) concerning the acquisition of ABH by Shire (the “Merger”).
In connection with the execution of the Merger Agreement, Safeguard, as well as each of the other principal stockholders of ABH, executed a Consent Agreement concerning their support for the transactions contemplated by the Merger Agreement (the “Consent Agreement”). Pursuant to the terms of the Consent Agreement, each stockholder party, among other things, has provided its consent to the anticipated transaction. Safeguard owns approximately 19% of ABH on a fully diluted basis.
Pursuant to the Merger Agreement, Shire will acquire ABH for a cash purchase price of $750 million, subject to adjustments related to ABH’s net cash, working capital, transaction expenses and similar items. The consummation of the Merger is subject to the satisfaction of standard conditions to closing, including, but not limited to, the expiration of any applicable waiting period under the Hart-Scott-Rodino Act. It is presently anticipated that the Merger will be consummated late in the second quarter or early in the third quarter of 2011.
Based upon its equity holdings in ABH, it is presently anticipated that Safeguard will receive aggregate cash proceeds of approximately $140 million in connection with the Merger based upon the terms of its stock preferences. Pursuant to the terms of the Merger Agreement, five (5%) percent of such amount will be held in escrow through March 31, 2012.
The foregoing summary of the Consent Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Consent Agreement attached hereto as Exhibit 10.1, which is incorporated herein by reference.
Cautionary Statement Regarding Forward-Looking Statements
This Current Report on Form 8-K includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, are forward-looking statements. These forward looking statements address, among other things activities, events or developments that Safeguard expects, believes or anticipates will or may occur in the future, including Safeguard’s statements relating to the proposed Merger. These forward-looking statements are subject to a number of risks that could cause actual results to differ materially from those contained in the forward-looking statements, including the risk that the regulatory approvals and any other required approvals in connection with the Merger may not be obtained on the proposed terms or at the times anticipated. Currently unknown or unanticipated risks, or risks that emerge in the future, could cause actual results to differ materially from those described in forward-looking statements, and it is not possible for Safeguard to predict all such risks, or the extent to which this may cause actual results to differ from those contained in any forward-looking statement. Except as required by law, Safeguard assumes no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events, or otherwise.
ITEM 7.01. Regulation FD Disclosure
On May 17, 2011, Safeguard issued a press release announcing the Merger and the entry into the Consent Agreement. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information furnished pursuant to this Item 7.01 and the accompanying Exhibit 99.1 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and is not to be incorporated by reference into any filing of Safeguard.

 

 


 

ITEM 9.01. Financial Statements and Exhibits
(d) Exhibits.
         
  10.1    
Consent Agreement, dated as of May 17, 2011, by and among Shire Pharmaceuticals, Inc. and certain stockholders of Advanced BioHealing, Inc.
       
 
  99.1    
Press release dated May 17, 2011
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  Safeguard Scientifics, Inc.
 
 
Dated: May 18, 2011  By:   /s/ BRIAN J. SISKO    
    Brian J. Sisko   
    Senior Vice President and General Counsel   

 

 


 

         
Exhibit Index
         
  10.1    
Consent Agreement, dated as of May 17, 2011, by and among Shire Pharmaceuticals, Inc. and certain stockholders of Advanced BioHealing, Inc.
       
 
  99.1    
Press release dated May 17, 2011

 

 

EX-10.1 2 c17563exv10w1.htm EXHIBIT 10.1 Exhibit 10.1
EXHIBIT 10. 1

EXECUTION VERSION
CONSENT AGREEMENT
This CONSENT AGREEMENT (this “Consent Agreement”), is dated as of May 17, 2011, by and among Shire Pharmaceuticals Inc., a Delaware corporation (“Parent”), and certain stockholders of Advanced BioHealing, Inc., a Delaware corporation (the “Company”), listed on the signature page hereto (each, a “Stockholder” and, collectively, the “Stockholders”). For purposes of this Consent Agreement, Parent and the Stockholders are each a “Party” and collectively the “Parties”. Unless otherwise defined herein, capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement (defined below).
WHEREAS, Parent, ABH Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”), the Company, solely for the purposes of Section 2.7 and Articles III, IX and X thereof, Canaan VII L.P., a Delaware limited partnership, as the Equityholders’ Representative, and solely for the purposes of Section 10.17 thereof, Shire plc, a public limited company incorporated under the laws of Jersey, Channel Islands, propose to enter into an Agreement and Plan of Merger dated as of the date hereof (the “Merger Agreement”) providing for, among other things, the merger of Merger Sub with and into the Company (the “Merger”);
WHEREAS, as of the date hereof, the Stockholders are collectively the record and beneficial holders of the shares of Company Capital Stock set forth next to their names on the signature pages hereto (the “Subject Shares”);
WHEREAS, pursuant to Section 251 of the DGCL, a majority of the outstanding shares of the Company Capital Stock (excluding the Series C-1 Preferred Stock) are required under the DGCL to vote to approve the adoption of the Merger Agreement (the “Required DGCL Approval”);
WHEREAS, pursuant to Section 4 of Article IV of the Company Certificate of Incorporation, the holders of shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock have the right to one vote for each share of Common Stock into which such shares are convertible and are entitled to vote, together with the holders of Common Stock, on any matters with respect to which the holders of Common Stock are entitled to vote;
WHEREAS, holders of a majority of the outstanding Company Capital Stock (excluding the Series C-1 Preferred Stock) voting or consenting, as the case may be, on an as-converted-to Common Stock basis are required to obtain the Required DGCL Approval;
WHEREAS, pursuant to Section 5(b) of the Company Certificate of Incorporation, in addition to the Required DGCL Approval, approval and adoption of the Merger Agreement and the Merger requires the affirmative vote or consent of holders of at least 60% of the outstanding shares of Series C Preferred Stock (the “Required Series C Approval” and, together with the Required DGCL Approval, the “Required Company Stockholder Approval”);

 

 


 

WHEREAS, as an inducement to Parent and Merger Sub entering into the Merger Agreement, the Stockholders, who hold sufficient shares of Company Capital Stock to constitute both the Required DGCL Approval and the Required Series C Approval, are entering into this Consent Agreement pursuant to which the Stockholders shall (i) execute a written consent in respect of all of the Subject Shares substantially in the form attached hereto as Exhibit A in favor of the proposal to approve and adopt the Merger Agreement and the Merger (the “Consent”) and (ii) agree to certain other matters, pursuant and subject to the terms and conditions hereof;
NOW, THEREFORE, in consideration of the foregoing premises and the mutual benefits to be gained by the performance thereof, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged and accepted, Parent and the Stockholders, intending to be legally bound, hereby agree as follows:
Section 1. Consent. Each Stockholder covenants and agrees to, promptly following the execution and delivery of this Consent Agreement and the Merger Agreement, consent to the approval and adoption of the Merger Agreement and the transactions contemplated thereby (including, among other things, the Merger) and shall deliver to the Company a Consent with respect to the Subject Shares.
Section 2. Acknowledgement. Each Stockholder confirms and agrees that the Merger constitutes a “Sale Transaction” as defined in the Company Certificate of Incorporation, and an “Approved Sale” for purposes of that certain Amended and Restated Investor Rights Agreement dated as of February 23, 2007.
Section 3. Treatment of Warrants. Each Stockholder that is a holder of Warrants agrees (i) not to exercise such Warrants prior to the Effective Time and (ii) that, at the Effective Time and in accordance with Section 2.6(e) of the Merger Agreement, all such Warrants shall no longer be outstanding and shall automatically be canceled and retired and shall cease to exist, and each Certificate which immediately prior to the Effective Time represented such Warrants shall thereafter represent the right to receive the Warrant Payment payable therefor and the right to receive payments from the Escrow Account in accordance with the Escrow Agreement and Section 3.3 of the Merger Agreement.
Section 4. Representations and Warranties. Each Stockholder represents and warrants to Parent and Merger Sub as follows:
  (a)   Such Stockholder is the record and beneficial owner of, and has good title to, all of the Subject Shares set forth next to its name on its signature page hereto, and there exist no Encumbrances affecting any such Subject Shares, except as imposed by applicable Laws or as set forth in the Company Disclosure Schedule.
  (b)   If such Stockholder is an entity, it is duly organized, validly existing and in good standing under the Laws of the jurisdiction of its organization.
  (c)   The execution and delivery of this Consent Agreement by such Stockholder does not, and the performance by such Stockholder of its obligations hereunder will not, constitute a violation of, conflict with, result in a default (or an event which, with notice or lapse of time or both, would result in a default) under or result in the creation of any Encumbrance on any of its Subject Shares under, (i) any Contract or restriction of any kind to which such Stockholder is a party or by which such Stockholder or its Subject Shares are bound, (ii) any applicable Law affecting such Stockholder or its Subject Shares or (iii) if such Stockholder is an entity, such Stockholder’s applicable organizational documents, in each case except as would not, individually or in the aggregate, reasonably be expected to prevent, enjoin, or materially delay or impair the performance by such Stockholder of the its obligations under this Consent Agreement.

 

 


 

  (d)   Such Stockholder has all requisite power and authority to enter into this Consent Agreement, to perform its obligations hereunder and to consummate the transactions contemplated hereby. The execution, delivery and performance by such Stockholder of this Consent Agreement has been duly authorized by all necessary action on the part of such Stockholder. This Consent Agreement has been duly executed and delivered by such Stockholder and this Consent Agreement constitutes a legally valid and binding obligation of such Stockholder, enforceable against such Stockholder in accordance with its terms, except as such enforceability may be limited by principles of public policy, and subject to (i) the effect of any applicable Law of general application relating to bankruptcy, reorganization, insolvency, or moratorium or similar Laws affecting creditors’ rights and relief of debtors generally and (ii) the effect of rules of Law and general principles of equity, including rules of Law and general principles of equity governing specific performance, injunctive relief and other equitable remedies (regardless of whether such enforceability is considered in a proceeding in equity or at Law).
Section 5. Waiver of Dissenter’s and Appraisal Rights. Each Stockholder waives, and agrees not to exercise, any right to dissent or appraisal or any similar provision under applicable Law in connection with the Merger.
Section 6. Equityholders’ Representative. Each Stockholder confirms and agrees (i) to the irrevocable appointment of Canaan VII L.P. as agent, attorney-in-fact and Equityholders’ Representative for and on behalf of such Stockholder (in his, her or its capacity as an Equityholder under the Merger Agreement) with all of the powers and authority contemplated by Section 10.1 of the Merger Agreement, (ii) that the Equityholders’ Representative shall have full power of substitution, to act in the name, place and stead of such Stockholder with respect to the Escrow Agreement and Section 2.7, Article III, Article IX and Article X of the Merger Agreement and the taking by the Equityholders’ Representative of any and all actions as it determines in its sole and absolute discretion to be necessary, advisable or appropriate in order to carry out and perform its rights and obligations under the Merger Agreement and the making of any decisions required or permitted to be taken by the Equityholders’ Representative under the Merger Agreement and the Escrow Agreement and (iii) that the terms and conditions of Section 10.1 of the Merger Agreement shall be and are binding on such Stockholder as fully as if such Stockholder were an original signatory to the Merger Agreement as an Equityholder thereunder. Each Stockholder agrees that service of process on the Equityholders’ Representative in accordance with the Merger Agreement shall constitute service of process on such Stockholder.

 

 


 

Section 7. Release. Effective as of the Closing, each Stockholder hereby releases, remises and forever discharges the Company from any and all liabilities and obligations to such Stockholder, whether arising prior to, on or after the Closing Date (so long as the events giving rise to the obligation or liability occurred prior to the Closing Date) except for (a) subject to Section 6.5 of the Merger Agreement, rights and claims for indemnification to the extent such Stockholder is entitled to be indemnified by the Company under applicable law, its organizational documents or agreement, (b) if such Stockholder is an employee of the Company, rights under any Company Benefit Plan (other than any such plan that provides for equity-based compensation), rights to earned but unpaid wages or compensation, unpaid vacation, or unreimbursed business expenses, and (c) such Stockholder’s right to full and complete payment for its Subject Shares in accordance with Articles II and III of the Merger Agreement and the Escrow Agreement or its rights to indemnification under Article IX of the Merger Agreement. Each Stockholder expressly waives any rights or benefits under §1542 of the Civil Code of the State of California and any similar provisions of the Law of any other jurisdiction. §1542 states: “A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.”
Section 8. Nonsolicitation. Each Stockholder hereby covenants and agrees that from the date hereof until December 31, 2012, such Stockholder will not, and will not permit its controlled Affiliates to, directly or indirectly solicit or hire any employee of the Company with a position or title of Vice President (or its equivalent) or above; provided, that this Section 8 shall not be construed to prohibit such Stockholder or its controlled Affiliates from (a) making any general solicitation of employment not specifically directed to such person or (b) soliciting or hiring any such person who, after the Closing, has been terminated by the Company or its Affiliates without cause or who terminates his or her employment with the Company or its Affiliates for good reason (which, for purposes hereof, shall have the meaning given such term in any applicable employment agreement and, if there is no applicable employment agreement, shall mean (i) a material diminution in such person’s employment duties as in effect immediately prior to the Closing, (ii) a material reduction in annual base salary, (iii) a change in the principal work location of over 50 miles from such person’s principal work location immediately prior to the Closing, or (iv) any material breach of an employment, severance or change in control agreement).
Section 9. Confidentiality. Each Stockholder acknowledges that the success of the Company after the Closing depends upon the continued preservation of the confidentiality of certain information possessed by such Stockholder, that the preservation of the confidentiality of such information by all of the Stockholders is an essential premise of the transactions contemplated by the Merger Agreement, and that Parent and Merger Sub would be unwilling to enter into the Merger Agreement in the absence of this Consent Agreement (including this 9). Accordingly, each Stockholder agrees with Parent that from and after the date hereof until the second anniversary of the Closing Date such Stockholder will not, other than for or on behalf of Parent or its Affiliate (including the Company), and will not permit its controlled Affiliates to, disclose or use any confidential or proprietary information of the Company; provided, that the information subject to the foregoing provisions of this sentence (the “Confidential Information”) will not include any information that: (a) is or becomes generally available to the public other than as a result (directly or indirectly) of a violation hereof; (b) was in such Stockholder’s possession and obtained on a nonconfidential basis prior to the disclosure thereof by the Company or its Affiliates; and (c) becomes available to such Stockholder on a nonconfidential basis from a person other than the Company or its Affiliates who to such Stockholder’s knowledge is not otherwise bound by any obligation of confidentiality with respect thereto; provided, further, that nothing in this Section 9 will restrict any Stockholder from using Confidential Information to the extent reasonably necessary in connection with enforcing its rights, or defending any claims against, arising from, pertaining to or relating to the Merger Agreement, this Consent Agreement, the Letter of Transmittal or any certificate or document delivered pursuant to any of the foregoing.

 

 


 

Section 10. Indemnification Matters. Each Stockholder hereby acknowledges the indemnification obligations of the Equityholders pursuant to Article IX of the Merger Agreement and agrees to be bound by and to perform all obligations applicable to an Equityholder thereunder in accordance with the terms and conditions of, and subject to all of the limitations set forth in, Article IX of the Merger Agreement as fully as if such Stockholder were an original signatory to the Merger Agreement as an Equityholder thereunder. If such Stockholder is entitled to indemnification following the Effective Time under Section 6.5 of the Merger Agreement, such Stockholder acknowledges its rights to such indemnification. Notwithstanding those rights, each Stockholder hereby agrees that the availability of the indemnification of the Parent Indemnified Parties by the Equityholders will be determined without regard to any right to indemnification or contribution which such Stockholder may have in his or her capacity as a Company Indemnified Party, and such Stockholder will not be entitled to any contribution or reimbursement from the Parent, the Company or any of their respective Affiliates for amounts paid, owed or owing to Parent Indemnified Parties on behalf of such Stockholder for indemnification of Parent Indemnified Parties under Article IX of the Merger Agreement by reason of the fact that such Stockholder was a Company Indemnified Party (whether such claim is for Damages of any kind and whether such claim is pursuant to any Law, organizational document, Contract or otherwise). With respect to any claim brought by a Parent Indemnified Party against such Stockholder under the Merger Agreement or this Consent Agreement, each Stockholder expressly waives any right of subrogation, contribution, advancement, indemnification or other claim against the Company with respect to any amounts owed or owing by such Stockholder pursuant to the Merger Agreement or this Consent Agreement.
Section 11. Entire Agreement; No Third-Party Beneficiaries. This Consent Agreement (together with the Consent) constitutes the entire agreement of the Parties and supersedes all other prior agreements and understandings among the Parties, with respect to the subject matter hereof. This Consent Agreement is for the sole benefit of the Parties to this Consent Agreement and nothing in this Consent Agreement, express or implied, is intended to or shall confer upon any other Person any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Consent Agreement.
Section 12. Governing Law; Consent to Jurisdiction. This Consent Agreement and the transactions contemplated hereby, and all disputes between the Parties under or related to the Consent Agreement or the facts and circumstances leading to its execution, whether in contract, tort or otherwise, shall be governed by, and construed in accordance with, the Laws of the State of Delaware applicable to contracts executed in and to be performed entirely within such State, without regard to conflict of law principles that would result in the application of any Laws other than the Laws of the State of Delaware. Each of the Parties to this Consent Agreement hereby irrevocably and unconditionally submits, for itself and its assets and properties, to the exclusive jurisdiction of any Delaware State court, or Federal court of the United States of America, sitting within the State of Delaware, and any appellate court from any thereof, in any Action arising out of or relating to this Consent Agreement, the agreements delivered in connection with this

 

 


 

Consent Agreement, or the transactions contemplated hereby or thereby, or for recognition or enforcement of any judgment relating thereto, and each of the Parties to this Consent Agreement hereby irrevocably and unconditionally (i) agrees not to commence any such Action except in such courts; (ii) agrees that any claim in respect of any such Action may be heard and determined in such Delaware State court or, to the extent permitted by Law, in such Federal court; (iii) waives, to the fullest extent it may legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any such action or proceeding in any such Delaware State or Federal court; and (iv) waives, to the fullest extent permitted by Law, the defense of an inconvenient forum to the maintenance of such Action in any such Delaware State or Federal court. Each of the Parties to this Consent Agreement hereby agrees that a final judgment in any such Action shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law.
Section 13. Miscellaneous.
  (a)   This Consent Agreement may be amended or modified only by a written instrument executed by all of the Parties to this Consent Agreement. Any failure of the Parties to this Consent Agreement to comply with any obligation, covenant, agreement or condition in this Consent Agreement may be waived by the party entitled to the benefits thereof only by a written instrument signed by the party granting such waiver. No delay on the part of any party to this Consent Agreement in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any waiver on the part of any party to this Consent Agreement of any right, power or privilege hereunder operate as a waiver of any other right, power or privilege hereunder, nor shall any single or partial exercise of any right, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, power or privilege hereunder. Unless otherwise provided, the rights and remedies provided for in this Consent Agreement are cumulative and are not exclusive of any rights or remedies which the Parties to this Consent Agreement may otherwise have at Law or in equity.
  (b)   EACH PARTY TO THIS CONSENT AGREEMENT ACKNOWLEDGES AND AGREES THAT ANY CLAIM OR CONTROVERSY WHICH MAY ARISE UNDER THIS CONSENT AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE, IT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS CONSENT AGREEMENT AND ANY OF THE AGREEMENTS DELIVERED IN CONNECTION WITH THIS CONSENT AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EACH PARTY TO THIS CONSENT AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE EITHER OF SUCH WAIVERS, (II) IT UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF SUCH WAIVERS, (III) IT MAKES SUCH WAIVERS VOLUNTARILY AND (IV) IT HAS BEEN INDUCED TO ENTER INTO THIS CONSENT AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 13(B).

 

 


 

  (c)   In the event that any one or more of the terms or provisions contained in this Consent Agreement or in any other certificate, instrument or other document referred to in this Consent Agreement, shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Consent Agreement or any other such certificate, instrument or other document referred to in this Consent Agreement. Any term or provision of this Consent Agreement held invalid or unenforceable only in part, degree or within certain jurisdictions shall remain in full force and effect to the extent not held invalid or unenforceable to the extent consistent with the intent of the Parties as reflected by this Consent Agreement. To the extent permitted by applicable Law, each party waives any term or provision of Law which renders any term or provision of this Consent Agreement to be invalid, illegal or unenforceable in any respect.
  (d)   Neither this Consent Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any of the Parties to this Consent Agreement (whether by operation of Law or otherwise) without the prior written consent of the other Parties to this Consent Agreement, and any purported assignment or other transfer without such consent shall be void and unenforceable, except that Parent may transfer or assign its rights and obligations under this Consent Agreement, in whole or from time to time in part, to one or more of its Affiliates at any time; provided, that such transfer or assignment shall not relieve Parent of its obligations hereunder or enlarge, alter or change any obligation of any other party hereto or due to Parent. Subject to the preceding sentence, this Consent Agreement shall be binding upon, inure to the benefit of and be enforceable by the Parties to this Consent Agreement and their respective successors and assigns.
  (e)   Each of the Parties to this Consent Agreement acknowledges and agrees that the other Parties to this Consent Agreement may be irreparably damaged in the event that any of the terms or provisions of this Consent Agreement are not performed in accordance with their specific terms or otherwise are breached. Therefore, notwithstanding anything to the contrary set forth in this Consent Agreement, each of the Parties to this Consent Agreement hereby agrees that the other Parties to this Consent Agreement may be entitled to an injunction or injunctions to prevent breaches of any of the terms or provisions of this Consent Agreement, and to enforce specifically the performance by such first party under this Consent Agreement, and each party to this Consent Agreement hereby agrees to waive the defense (and not to interpose as a defense or in opposition) in any such suit that the other parties to this Consent Agreement have an adequate remedy at Law, and hereby agrees to waive any requirement to post any bond in connection with obtaining such relief. The equitable remedies described in this 13(e) shall be in addition to, and not in lieu of, any other remedies at Law or in equity that the Parties to this Consent Agreement may elect to pursue.
  (f)   This Consent Agreement will automatically terminate if the Merger Agreement is terminated prior to the Effective Time.
  (g)   This Consent Agreement may be executed in one or more counterparts, each of which when executed shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement. In the event that any signature is delivered by facsimile transmission, or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the Party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” format data file signature page were an original thereof.
(Remainder of Page Intentionally Left Blank)

 

 


 

IN WITNESS WHEREOF, each Party has duly executed this Consent Agreement, all as of the date first written above.
         
  SHIRE PHARMACEUTICALS, INC.
 
 
  By:   /S/    
    Name:      
    Title:      
 

 

 


 

         
  CANAAN VII L.P.
 
 
  By:   Canaan Partners VII, LLC
 
 
  By:   /S/    
    Name:      
    Title:      
 
  Series B Preferred Stock: 933,509
Series C Preferred Stock: 2,811,330

WHEATLEY NEW YORK PARTNERS, L.P.
 
 
  By:   Wheatley NY Partners, LLC, its general partner
 
 
  By:   /S/    
    Name:      
    Title:      
 
  Series B Preferred Stock: 300,036
Series C Preferred Stock: 536,456

WHEATLEY PARTNERS III, L.P.
 
 
  By:   Wheatley Partners III, LLC, its general partner
 
 
  By:   /S/    
    Name:      
    Title:      
 
  Series B Preferred Stock: 139,991
Series C Preferred Stock: 276,005

WHEATLEY ASSOCIATES III, L.P.
 
 
  By:   Wheatley Partners III, LLC, its general partner
 
 
  By:   /S/    
    Name:      
    Title:      
 
Series B Preferred Stock: 29,208
Series C Preferred Stock: 31,503  
 
 

 

 


 

         
  WHEATLEY FOREIGN PARTNERS III, L.P.
 
 
  By:   Wheatley Partners III, LLC, its general partner
 
 
  By:   /S/    
    Name:      
    Title:      
 
  Series B Preferred Stock: 30,823
Series C Preferred Stock: 50,129

SAFEGUARD DELAWARE INC.
 
 
  By:   /S/ Brian J. Sisko    
    Name:   Brian J. Sisko   
    Title:   Vice President   
 
  Series C Preferred Stock: 2,212,248
Series C Preferred Stock: 779,170

CHANNEL MEDICAL PARTNERS, L.P.
 
 
  By:   Channel Medical Management, LLC,
its general partner
 
 
  By:   Channel Medical Advisors, Inc.,
its manager
 
 
  By:   /S/    
    Name:      
    Title:      
 
  Series C Preferred Stock: 691,327

HUTTON LIVING TRUST dated 12/10/96
 
 
  By:   /S/    
    Name:      
    Title:      
 
  Series B Preferred Stock: 4,691
Series C Preferred Stock: 19,939  
 
 

 

 


 

EXHIBIT A
Advanced BioHealing, Inc.
Written Consent of Stockholders
May 17, 2011
Reference is made to the Agreement and Plan of Merger, dated as of May 17, 2011 (the “Merger Agreement”), by and among Shire Pharmaceuticals Inc., a Delaware corporation (“Parent”), ABH Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of Parent (“Merger Sub”), Advanced BioHealing, Inc., a Delaware corporation (the “Corporation”), and solely for purposes of Section 2.7 and Articles III, IX and X thereof, Canaan VII L.P., a Delaware limited partnership (the “Equityholders’ Representative”), and solely for the purposes of Section 10.17 thereof, Shire plc, a public limited company incorporated under the laws of Jersey, Channel Islands, an executed copy of which is attached hereto as Exhibit A, and the Consent Agreement by and among Parent and the Stockholders, as defined below. Unless otherwise defined herein, capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement.
The undersigned, being stockholders of the Corporation (the “Stockholders”) holding the shares of the Company Capital Stock set forth next to their name on the signature page hereto (the “Subject Shares”), which constitute both: (i) at least a majority of the outstanding Company Capital Stock (excluding the Series C-1 Preferred Stock) on an as-converted-to Common Stock basis and (ii) at least 60% of the shares of Series C Preferred Stock, hereby consent to and adopt, pursuant to Section 228 of the DGCL, the following resolutions:
WHEREAS, the Stockholders have notified the Board of Directors (the “Board”) of the Corporation that the Purchasers and the Junior Holders (each as defined in that certain Amended and Restated Investor Rights Agreement dated as of February 23, 2007 (the “Shareholders’ Agreement”)) have determined to initiate and consummate an Approved Sale (as defined in the Shareholders’ Agreement) in accordance with Section 3.1 of the Shareholders’ Agreement;
WHEREAS, it is contemplated that, subject to the terms and conditions set forth in the Merger Agreement, Merger Sub will be merged with and into the Corporation (the “Merger”) with the Corporation continuing as the surviving corporation of the Merger; and
WHEREAS, the Board has unanimously (i) approved and declared advisable the Merger Agreement, (ii) determined that the transactions contemplated by the Merger Agreement are advisable, fair to and in the best interests of the holders of outstanding shares of Company Capital Stock, (iii) recommended the approval and adoption of the Merger Agreement and the transactions contemplated thereby, including without limitation, the Merger, to the Stockholders and (iv) directed that the Merger Agreement be submitted to the Stockholders for their approval and adoption.
NOW, THEREFORE, BE IT RESOLVED, that each Stockholder signing below hereby votes in favor of, consents to, and adopts, approves, ratifies and confirms, the Merger Agreement, and each of the other transactions, agreements, documents and deliveries contemplated by the Merger Agreement, including without limitation, the Merger, the form, terms and amount of the Merger Consideration and the nomination and appointment of the Equityholders’ Representative.
 

 

 


 

Each Stockholder executing this Consent and acting in accordance with Section 5(a)(viii) of Article IV(B) of the Company Certificate of Incorporation hereby votes in favor of, consents to, and adopts, approves, ratifies and confirms, the management incentive plan pursuant to which eligible participants may receive bonuses upon the closing of the Merger, which management incentive plan is intended to (a) maximize stockholder value by retaining key employees through the closing of the Merger, (b) create incentives for management to consummate the Merger thus maximizing stockholder value, and (c) fairly compensate the Corporation’s key employees for past contributions to the Corporation.
Each Stockholder executing this Consent understands and acknowledges that by executing this Consent such Stockholder is waiving any right to dissent or appraisal or any similar provision under the DGCL that it may have with respect to the transactions contemplated by the Merger Agreement.
Each Stockholder executing this Consent represents and warrants to the Corporation, Parent and Merger Sub that it is familiar with the terms and conditions of the transactions contemplated by the Merger Agreement by virtue either of its participation in the negotiations regarding the Merger Agreement or the provision to it of detailed descriptions thereof and has been given the opportunity to ask questions of, and receive answers from, the Corporation concerning the terms and conditions of the Merger Agreement.
Each Stockholder executing this Consent that is a director, officer, employee or agent of the Corporation represents and warrants to the Corporation, Parent and Merger Sub that it is executing this Consent voluntarily and not as a condition to the continuation of his or her employment with the Corporation and that such director, officer, employee or agent has not been threatened with any adverse treatment by the Corporation if he or she did not execute this Consent.
The action taken by this Consent shall have the same force and effect as if taken at a meeting of stockholders of the Corporation, duly called and constituted pursuant to the DGCL. This Consent may be signed in any number of counterparts, including without limitation by facsimile, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.
This Consent shall be irrevocable, and any vote, consent or other action by each Stockholder executing this Consent that is not in accordance with this Consent shall be considered null and void; provided, that notwithstanding anything else to the contrary herein, this Consent shall terminate and be of no further force and effect upon termination of the Merger Agreement with no further Liability or obligation of any Stockholder hereunder. Each Stockholder executing this Consent shall not enter into any agreement or understanding with any person prior to the termination of the Merger Agreement to consent, vote, give instructions or take any other action in a manner inconsistent with this Consent.
Parent shall be a third party beneficiary hereunder, with the power of enforcement.
(Remainder of Page Intentionally Left Blank)
 

 

 


 

IN WITNESS WHEREOF, the Stockholders have signed this Consent as of the 17th day of May 2011.
         
  CANAAN VII L.P.
 
 
  By:   Canaan Partners VII, LLC
 
 
  By:   /S/    
    Name:      
    Title:      
 
  Series B Preferred Stock: 933,509
Series C Preferred Stock: 2,811,330

WHEATLEY NEW YORK PARTNERS, L.P.
 
 
  By:   Wheatley NY Partners, LLC, its general partner
 
 
  By:   /S/    
    Name:      
    Title:      
 
  Series B Preferred Stock: 300,036
Series C Preferred Stock: 536,456

WHEATLEY PARTNERS III, L.P.
 
 
  By:   Wheatley Partners III, LLC, its general partner
 
 
  By:   /S/    
    Name:      
    Title:      
 
  Series B Preferred Stock: 139,991
Series C Preferred Stock: 276,005

WHEATLEY ASSOCIATES III, L.P.
 
 
  By:   Wheatley Partners III, LLC, its general partner
 
 
  By:   /S/    
    Name:      
    Title:      
 
  Series B Preferred Stock: 29,208
Series C Preferred Stock: 31,503  
 
 

 

 


 

         
  WHEATLEY FOREIGN PARTNERS III, L.P.
 
 
  By:   Wheatley Partners III, LLC, its general partner
 
 
  By:   /S/    
    Name:      
    Title:      
 
  Series B Preferred Stock: 30,823
Series C Preferred Stock: 50,129

SAFEGUARD DELAWARE INC.
 
 
  By:   /S/ Brian J. Sisko    
    Name:   Brian J. Sisko  
    Title:   Vice President  
 
  Series C Preferred Stock: 2,212,248
Series C Preferred Stock: 779,170

CHANNEL MEDICAL PARTNERS, L.P.
 
 
  By:   Channel Medical Management, LLC,
its general partner
 
 
  By:   Channel Medical Advisors, Inc., its manager
 
 
  By:   /S/    
    Name:      
    Title:      
 
  Series C Preferred Stock: 691,327

HUTTON LIVING TRUST dated 12/10/96
 
 
  By:   /S/    
    Name:      
    Title:      
 
  Series B Preferred Stock: 4,691
Series C Preferred Stock: 19,939 
 
 

 

 


 

Pursuant to the rules of the U.S. Securities and Exchange Commission, the attachment to Exhibit A to the Consent Agreement has not been filed herewith. Safeguard agrees to furnish supplementally a copy of such attachmenxt to the U.S. Securities and Exchange Commission upon request.

 

 

EX-99.1 3 c17563exv99w1.htm EXHIBIT 99.1 Exhibit 99.1
EXHIBIT 99.1
     
(SAFEGUARD LOOG)   FOR IMMEDIATE RELEASE
CONTACT:
John E. Shave
Vice President, Business Development and Corporate Communications
610.975.4952
SAFEGUARD SCIENTIFICS PARTNER COMPANY ADVANCED BIOHEALING
TO BE ACQUIRED BY SHIRE FOR $750 MILLION
Sale Expected to Generate More than 13x Cash-on-Cash Return and More than $140 Million in
Net Proceeds for Safeguard
Third Substantial Exit Transaction for Safeguard in Six Months
Wayne, PA, May 17, 2011 Safeguard Scientifics, Inc. (NYSE: SFE), a holding company that builds value in growth-stage life sciences and technology companies, today announced that life sciences partner company Advanced BioHealing, Inc. (ABH) has signed a definitive agreement to be acquired by Shire plc (LSE: SHP, NASDAQ: SHPGY).
Shire has agreed to pay $750 million, in cash, for ABH in a transaction that is expected to close late in the second quarter or early in the third quarter of 2011. It is anticipated that Safeguard will receive aggregate cash proceeds of more than $140 million in connection with the transaction, which represents a more than 13x cash-on-cash return. Five percent of such proceeds will be held in escrow pending the expiration of an escrow period expiring on March 31, 2012. The consummation of the transaction is subject to the expiration of the applicable waiting period under the Hart-Scott Rodino Act and the satisfaction of other standard closing conditions.
“Safeguard’s value-creation momentum continues to build with Shire’s acquisition of ABH, which represents our third substantial exit transaction in the past six months,” said Peter J. Boni, President and CEO of Safeguard Scientifics. “By adhering to a disciplined strategy, we have been able to support our partner companies financially and operationally to drive growth. Since we deployed capital in ABH in February 2007, the company increased revenues from a standstill to approximately $150 million in 2010. In addition, the company established robust commercial and scaled cell-based manufacturing infrastructures. We are proud of ABH’s success in building a premier regenerative medicine company.”
Headquartered in Westport, CT with additional facilities in La Jolla, CA and Nashville, TN, ABH manufactures and markets Dermagraft®, a bio-engineered living skin substitute that assists in restoring damaged tissue and supports the body’s natural healing process. Dermagraft is FDA approved to treat diabetic foot ulcers Dermagraft also is the focus of an ongoing pivotal trial to assess the product’s safety and efficacy in the promotion of healing venous leg ulcers.
“Diabetes is a growing epidemic not only in the United States but around the world,” said Gary J. Kurtzman, MD, Managing Director in the Life Sciences Group at Safeguard and Board Member at ABH. “ABH has transformed the way diabetic foot ulcers, a significant complication of diabetes, are being treated, while also offering a possibility to extend Dermagraft’s utility to other areas of wound healing. As a result of its tremendous progress and market penetration over the past few years, world leading specialty biopharmaceutical company, Shire, has taken notice. We are confident that Shire will continue ABH’s mission to ‘enable people with life-altering conditions to lead better lives’.”

 


 

ABH’s acquisition by Shire Pharmaceuticals represents Safeguard’s third substantial exit transaction in the past six months. In December 2010, Clarient was acquired by GE Healthcare for $587 million. Safeguard realized a total of more than $200 million in cash from the sale of its equity interests in Clarient between 2009 and 2010, representing the largest cash return in Safeguard’s history. In addition in December 2010, Avid Radiopharmaceuticals was acquired by Eli Lilly for an upfront payment of $300 million and up to $500 million in additional contingent payments based on Avid’s achievement of certain challenging regulatory and revenue milestones.
“This tremendous achievement could not have been realized without the support of our investors and commitment of our employees,” said Kevin Rakin, Chairman and Chief Executive Officer for ABH. “Four years ago, we started with a vision to transform the regenerative medicine marketplace. Today, we find ourselves embarking on an exciting chapter in our company’s history. We are revolutionizing the way diabetic foot ulcers are being treated and have other indications under review. Our goal is to improve the lives of our patients and their caregivers and believe that Shire is the perfect partner to augment this vision.”
About Safeguard Scientifics
Founded in 1953 and based in Wayne, PA, Safeguard Scientifics, Inc. (NYSE: SFE) provides growth capital for entrepreneurial and innovative life sciences and technology companies. Safeguard targets life sciences companies in Molecular and Point-of-Care Diagnostics, Medical Devices, Regenerative Medicine, Specialty Pharmaceuticals and selected healthcare services, and technology companies in Internet / New Media, Financial Services IT, Healthcare IT and selected business services with capital requirements of up to $25 million. Safeguard participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings. For more information, please visit our website at www.safeguard.com, our blog at blog.safeguard.com or you can follow us on Twitter at twitter.safeguard.com or on LinkedIn at linked.safeguard.com.
About Advanced BioHealing, Inc.
Advanced BioHealing develops and commercializes living cell-based therapies that repair damaged human tissue and enable the body to heal itself. ABH currently manufactures and markets Dermagraft®, a bio-engineered skin substitute that assists in restoring damaged tissue and supports the body’s natural healing process. Dermagraft is FDA approved to treat diabetic foot ulcers and is the focus of an ongoing pivotal trial to assess the product’s safety and efficacy in the promotion of healing venous leg ulcers. A privately held company, Advanced BioHealing maintains its corporate office in Westport, Conn. with additional sites in La Jolla, Calif. and Nashville, Tenn. To learn more about Advanced BioHealing, please visit the Company’s web site at www.ABH.com.
About Shire plc
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. For further information on Shire, please visit the Company’s website: www.shire.com.
Forward-looking Statements
Except for the historical information and discussions contained herein, statements contained in this release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Our forward-looking statements are subject to risks and uncertainties. The risks and uncertainties that could cause actual results to differ materially, include, among others, managing rapidly changing technologies, limited access to capital, competition, the ability to attract and retain qualified employees, the ability to execute our strategy, the uncertainty of the future performance of our companies, acquisitions and dispositions of companies, the inability to manage growth, compliance with government regulations and legal liabilities, additional financing requirements, the effect of economic conditions in the business sectors in which our companies operate, and other uncertainties described in the Company’s filings with the Securities and Exchange Commission. Many of these factors are beyond our ability to predict or control. In addition, as a result of these and other factors, our past financial performance should not be relied on as an indication of future performance. The Company does not assume any obligation to update any forward-looking statements or other information contained in this news release.
# # #

 

GRAPHIC 4 c17563c1756301.gif GRAPHIC begin 644 c17563c1756301.gif M1TE&.#EAR``M`.8``%^1L-CC[0P-4&YRD$E+<]':YKG&U3`S:K+4B>/FZEV: M7O___/K\Z/[^].KS]O3Z^J3,7:FKMC1PJO#WSOG\^T(#H_;K>[TB1.E/#T],;+V_[Z_/3Z]4.6 M*%MDDO+V^(6^'?S\_"8J5.7SY_GZ^9"PR'%ZG^GTL+33.A`G=_[^^IK*&=ON MRYVEMH*Q4_G\]LG4W(2,HADV@_W^_)*:L_[[^OW^_@\58<7AJOW^[WV9N9.8 MJ*JSQ-/7W/S]^2YFG/[^]Z&FQ`X20]'GD/W^^?S\^/[]_?SV^?K\\?CY]_WZ M]5NH(A\A5+'4WJRYT8:W@HR/J_[\]OS]]O?[^Y>;P4E[H+G9N;[!U\/'S??V M]OO]_2I;GAY"C(*)L&R1,I_!TWN!E%%L+IS$+?SZ[T*#1]WO?<3=Q/3Y[7NL MQ5]@ACQ]M-W@YGM_JE*=).WO\A<84U^B)B(D8_[^_O_^_O___R'Y!``````` M+`````#(`"T```?_@'^"@X1!?5$<'%(<03Y37H:))GUE7@]!A)F:FYR=GI^@ MH:*CI*6FHB8<465EAT`U7%(6J8A555Q[O+V^O\#`7!P^K$!`'!D/'04[ M6%@!)%2XNL'6U]C9VIM)3\6)0,M8!@=J4HR@R*^BRCH`@HXAX2.FS)I(DP)S M<$3)F9,G^:D$`P-:!Q=VJ!Q2RK6K)YA&59514>2,V1$[H_(#H*;#@PSU_R@D M\A%DHY\H4?SHU?MG05%!"_3BW=NGAJ"8,`<9%>1GP8(^A@S=/>C':!_'-?3V M\<')\8),E^T]:53C[Z#/GQ!3'AS$4.D^E3E+WA@X9FW(,>DV:FTO<.P:L#=S M_@.YC(_C03A8N%FVQUFH2BC""."%;ID,%*:0H:+#2X8JQQ(-UE7CR1-!#8#, MPLN>R.?C95H#]A$%DY\:2Y;4:&7<#Z,_],47Q1(--,"!'SY0X-EGF"R`WQ*H M'>;#$E,PD%T#2R3!V`)+G+9@(:Q@@H@)47B71`-=()+,`F6H:$\-JW"Q0!"L MP'==%ZR/NA`!&P)4@#;=9E`0<$#/[30@_]S9Z#E)!@[/,""%"8HXT(8 M6BB@I19AN)`!"UTP`&&$IPF82"+7>9%7.\?YL$`4GB'"!8;V'/=FC66\M1&- MJF3@18N5T1@?;*L80IP/+*292&5)0#BBAY[]L==CF/PQ8I6&1-%7#0\M411> M(58B2(C^J<)@B);Z0>-P3W21GBH31@@%"4<<0,.23#I9!'5GRC%$EF]L\,&P MPVIQPQ0H8IC?8WIQB&$?',RYQ!/7$;I1'^858T)^3W!@`A#30EO#N%&\V``1 M3Q3GPS%1/+$$!WZU>=Q=K5Q6PYDF6'!@:X;>I2E@']ZG2TR,X55EBPMK8`!0:$0,/)2YK5)`X=G,`" M!7+<`,$>**"PP7@@\:QT,T?XI7!L`])L(#7<9L"5Q<]W1;J0P(I"'$R MRDN&`(,#B8"=_04[4%%#:WCAP`M44(#I M44]Z)>@`),Z4O>Y!3PPE"(`*,N"#+B0A#W:P0P(HJ(HHZ*`,6[B"YC;7@UNI MX0'1`L($()`##WC`=*A+G>J&E0,XO.XZ9>B"07Z2",(86A"`!^CH&%/(0`R(>8`P- M8$4&%I",(T01CE[4`Q_H8`<3Y&L`;BRC'O1P@"W8H?^*8^#!&G#P@"BDHD<% M:($01DC"(SQ`"K*8P`Q6L`(0@."%>(BAZE"@@!Q```,5F$`BR]"M*B3A!%MP M8PA^(`(#B``'*5!F`![PAU0D@0(=`*(0!'"``.@@"34@@@7*4()-IB`&Z$PG M.G'@@!1PC""*0/`!SU$X"`+^DP9 MC-"$/UJ`!<=XP1$$(``R#D`'4,BA.#-P!WRJ\PXQ2,$!*!J"/)B`!"T0@`;4 M.0`-\"&(,`:QKA*5GYA@AQ@@`QFT`9:UM*%5L@E+[4P M!!>X0`85P``P)T"$5FQ+!W;_%$`*J-,X973@!T3D@9HX8,$'\("33'`C$[S0 M!RGHL`QBT,,51*""NMJUKE2@@`94>M>^4N$%6;A"$S10`A)@E`464`$;N6D' M%@3@"@8%4@TBE8$?--0.JX@"$#I`!ZVZDP]VT.&$?,!1;CK@KD@K0`R$>`$* M..">6SAM71W0`2088:0'R,()&,""*8VS6W88:4]7F<\.9"`*0HVJ#6Q@5%N: M+@<(N($<2$`&"PQ5JAB``P/*P`+`Z<``^-2M#MR`C$2I0`-7H`,=:]`%'00@ M!`(80`<(H-($Y(L"R(CK%5J;A#(LH0NDK1T+]JH!';"`<>W5`04HX`4[[)4` M2/@@_Q1(2P$W/"`+(0C!&+SPV,@B:+)TJZP`0H!95D3!D7HH00GX((0UD($8 M21A&1P]``@L*C0A>**<`C)`!E.[8"T^XA3=\X(4+\$&E>6``%]0#A"Y`@041 M".)PA4"`X'%@"E#%[G+;D(9;0G<"4UBRMZIP7:G.0`9)0`047G"!\)Y`!P;2 M+(PZ$`#CE@$*53@!#K@I!B],5`],^%8&H,`!$TT! M%#3V7QWHX&TX$((>Q##H\F*'"#K`G@/D0($.'S1KCJF,B/](9#]IH`D$(($7 M.GN`!'`A"1G@`A1F3`)0QY@+H"Z`&W&@@SRDE,=`X`+&*O]3AM7J`0D-N)<] M,/0`.G"QIWS(@@-TP($)1!6[&)@!&YK`!@C(P`U52L*D_<``)[0!W'"@2QF(4#1CH`%9@@#_#5``GND00.Q)4/%Y@"$;K` MZ"[TM@H<(+"!*32%*@(A"BKH;`A0B"\.0$'B0R9"#1(@P@@D!QF'P(L7?C#B M!.":`A>`;`0^?H1[XD#B6FO`C.70`!VXB@%$R,,7!*"''=SDGD;H+@<$,1@. M]%P`3"C#>YX0[01$D:)@'P`)6A$%;X-[!FD0;!/6D(<72,&)>/G#"I>+73@T M(`C=@H(*8K!-(1R```/8`OS^5"'_.;"/"DRH:`F\P($R@%4/6:!`$J#U\"U, M+PL.?+$%]AH"Z;WO?78HPWP%$(.'Q/T%T'M?]Y#0!Y8;=$)!`TP?9EYSXI#@ MP8M@03M'W`$G,W'&$.3G&$J``SI`]@YD\($*H)X$U*#&#R;8P4C1X%_4P$C' M8,C`%S0`1+!+\@`I MB,";DYW%^)*@"@2"<`)``'G@!H<05YJV20K8!`=@!T"0`1JP2D.D@)NT!1P& M7UN@`U/0!_V5``=`@7*U!F5@:L2T!#52%)754/;U`F.P23C`!4O`!2?09DW` M!-.P"G>P_TH@N$GIQ01Y@`ROM6,ZD"Y!X!M^4`4%`%]W4`;1]AFW$U?9)P!T M`#J6!C;)A0$Y,'X4%5`D<'XFMT*T1'?9Q0!]X&1`T``40`8)<`0#0``AT`(B M1%$'(`(GH&P74$2M!39$MEI7@`1%V(@1 M\`+O)0`\`&<<`#;SE6$9YD8#D`$DZ`.--RA_L&IV($"K%0)(\''8D0#P!495 MX`==T%%"@(DA\('XQ`2O!(3'1@%%P1%XT0!(H(1!,"9_D`0Z`(5@UP13M&#F M,2Y"E85<](Q7<`3@<64R4%0KL'XS``?#8$&OH`,6H!Y]\``.4/\`68`&;<1[ M1*`"`X!/)9!!`?".3'!D:,`=<"5)=*@"#_``WH$=#3`%!'8")Y"/#Q"03M1_ M`U"'^N(%)W!:#D!;6C0`7M`!.H<7#Y@!A^`'+\!0),8!=G!/,5``=O".`5`` M:"`$?"`&^I($'14"'="0M,4$(^505:![4$=VC8%^#6``*?4%09`9>A$[!7!/ M8'<`'4`!<'$N4W`"'6`$4;1*4=@$$9`(4+!"(&!4UWAFB*!N?9`'>5!=^;,9 M1BD'/+!*)<``1O9&9511!X`$4P`$8M`$^]4%76"1CE$,77`"D68!DX87;N,X M9$!K'7`,)K!@5-!XRJ!%:T`!+"<$6X#_6,2@.*K@!5LP@`E`!5NP31151E*6 M`G3D!Z6H`I7@'7YV9#%`!DO@!0YP;"\`<_H!!(SV>#M0-YJ1!&1`7V!'!UYP M"T3```WP``:0`C0P9<=X!W0$!0R``!Y@2U893(D`(U)`!R&P!K*F=7.RFV9Y M9&/P!)^5`MS9G720`A$H`%M`!5+P3!^XT`%AQ9"'0G=Z9`O#%!V.@'BMI MFL=AG.HH`%=0`@J6FCN6!!^',:6130/H$HRA%SY`!6(@E$VP!7V8)$@4-0`4E,%(I M(&M!:`3,,TY[\P!(0%\M<`&8`$#@H'<_<&0"$`%4P`QJ8!)G@"LRVE,Q8`=3 M$`4L<`.EXT+)6940,`'I0@2X,`4&<$\:8`"5N68JD``1`$1TP%G<5`!R,*9$ M,`4MX@958&B,Z04/)P:*Y"F>D4@$E@`:E`#8>JUY4&2X]0-(0`).E/\!)Y`' M)0!?`]`%0!"/0D`')="5#]"K1T!??Y2$4D@&BU`Q#;,$!JI]I14"=)0=1``$ M24`":,!T8R".]\0#&I1!2'`!:`!?!_`%RN,'#T%H<^$G3!`"/5`$,%`$8#`" M30*RI'HRFG8'V]8`?7`#6I`&5N"JK^H$4^`F#0"`$#&6&$H'6_`%Y:-%#54" M.W!/!YF>-8`A>=$``PM?)&9H93%<"7GD?'62"69!28A<##>4` MU^$CKY`!!?!2`Y`''/IWA/B&6T0`8B`\!Y+_+>)Q'";@`%@`!BD1'2>!%F81 MHS0PAP\@>5W@`CF`!Z;3LJX*`7)0*8?!`GU`!EF`7FZ4F5=P`&A@!Y)Y!2$@ M!AJH)NSA(,KP!2W0`DS01RTP!B;V+W59;5?`!\B;O,A[!5<0`P^@`P\0`&AP M`)S:17K0`AK@@VZC`R3P0YMD?WR@`;*;!P207GE@:0&D"C%1!@DP`+0;`#S0 M`@1P":IP'Y0PNP=@``X0`LJ+O`>@`46P`V10'YM0&JP`?9`+!@%!N5`!LF=P M*U#B!512!:R*`J<#NE8@ND[0!8=!,`2S#`T;`3@0`4>00*N9`=::`+N5GFNB M"T;RKAG4,AI$%/=B_QA.&S[6FD$ZO,-VD`=$T`"D]0`)4`)'@`-&?`%CD``3 M%`2.\XT12<1&?`078`4"F%(2DWU0?Z8@&WP$0`-"Y`""*``&U`S*)!+A@P!+@`$ED$_DFB^$9]Z(*@#,NI<$>M;.^DG=@D]4'J,M$E4@C;J-L M?Q`BAS`N2]0S3W!^R$`(#M)HRWC/K[`1'70MN0$R+OTXQX&ZU_PO@]`P'/`$ M&)4(T:L&11`4C@P$ M?F$IM1,I\^$@+U(9&^'2SW=%3ZT8J\`U\<$;;?(9D%$?;M,:UW%K360!%SU](1\))JA'$(5$T<6[B&?)Q"@N`:U:DOI@`3AZ3`%'J`G&0)3GSX:J3`RZ0!+1@PZ80!-=D MI(RC`\F1,,^'%YX"(`WP_QD.@AJ;X3/HG=6E,MCV/%EYP]\)%1CL0=S_'>`% M8L/Q`BUP,M:/TPCFT1?Y40,Q*Q->S0J[\,.ZT2BTXP7"O-U:@MG=#>(;8"Q0 M$$A#2]X`KMK$03:6!&.XG`JJ[2_>L!F>\C@Q\=1TC0A-]BF)H-K'@=NJHDC. M+9LR`1NI)A.PYY-/;4K-^3^X;0\OG1;$[0GCTL%N>RV=P=S-Z[..B-?!3!K>NB M0-A\(1C-`M6:T-QX8^O$+NM\<0IXD2FA/NJD_@%OH`4NP.7UXA78GNV=T!J5 M\5L'%$`"@QSMTQX&)&"4)K;LVI[NV1X?D^$M5+#=8/X&"J`%2$`%J0`30M,. MZK[O7>$O%L`1C:<")&`0&P$%9&"DB;`(^L[O#%\3/PX@,P(63^T7UA+K#7_Q %\!`(`#L_ ` end